These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30066853)

  • 1. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
    Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
    Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
    Coffey GP; Feng J; Betz A; Pandey A; Birrell M; Leeds JM; Der K; Kadri S; Lu P; Segal J; Wang YL; Michelson G; Curnutte JT; Conley PB
    Clin Cancer Res; 2019 Feb; 25(4):1174-1184. PubMed ID: 30333224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
    Guo A; Lu P; Coffey G; Conley P; Pandey A; Wang YL
    Oncotarget; 2017 Feb; 8(8):12953-12967. PubMed ID: 28088788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
    Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
    Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Eur J Pharmacol; 2020 Apr; 872():172953. PubMed ID: 31996318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
    Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
    J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy.
    Ishikawa C; Senba M; Mori N
    Invest New Drugs; 2021 Apr; 39(2):317-329. PubMed ID: 32959166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2017 Aug; 51(2):633-643. PubMed ID: 28586006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
    Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
    Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
    J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
    Hamlin PA; Flinn IW; Wagner-Johnston N; Burger JA; Coffey GP; Conley PB; Michelson G; Leeds JM; Der K; Kim Y; Sabalvaro-Torres A; Birrell M; Pandey A; Curnutte JT; Patel MR
    Am J Hematol; 2019 Apr; 94(4):E90-E93. PubMed ID: 30592080
    [No Abstract]   [Full Text] [Related]  

  • 15. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
    Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
    Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.
    Fauzi YR; Nakahata S; Chilmi S; Ichikawa T; Nueangphuet P; Yamaguchi R; Nakamura T; Shimoda K; Morishita K
    PLoS One; 2021; 16(8):e0256320. PubMed ID: 34407152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
    Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
    Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
    Ishikawa C; Mori N
    Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol.
    Machijima Y; Ishikawa C; Sawada S; Okudaira T; Uchihara JN; Tanaka Y; Taira N; Mori N
    Retrovirology; 2009 Jan; 6():7. PubMed ID: 19146708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
    Tomita M; Kawakami H; Uchihara JN; Okudaira T; Masuda M; Matsuda T; Tanaka Y; Ohshiro K; Mori N
    Retrovirology; 2006 Apr; 3():22. PubMed ID: 16603085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.